<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00711854</url>
  </required_header>
  <id_info>
    <org_study_id>08-059</org_study_id>
    <nct_id>NCT00711854</nct_id>
  </id_info>
  <brief_title>Randomized Clinical Trial to Compare a Regimen of Trimethoprim-sulfamethoxazole Plus Rifampicin With a Regimen of Linezolid in the Treatment of Methicillin-Resistant Staphylococcus Aureus (MRSA) Infection</brief_title>
  <official_title>Randomized Clinical Trial to Compare a Regimen of Trimethoprim-sulfamethoxazole (TMP-SMX) Plus Rifampicin With a Regimen of Linezolid in the Treatment of Infections Caused by Methicillin-resistant Staphylococcus Aureus (MRSA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Geneva</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Geneva</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      MRSA infections often require systemic antibiotic therapy and represent an important&#xD;
      healthcare burden. Currently available treatment options are either only available in&#xD;
      parenteral form (vancomycin) or expensive (linezolid). Thus, there is an urgent, unmet need&#xD;
      to better investigate in-expensive but highly active alternatives to currently recommended&#xD;
      standard treatment options. The purpose of the proposed study is to test the hypothesis that&#xD;
      a combination of TMP-SMX and rifampicin is not inferior to linezolid for treatment of MRSA&#xD;
      infections.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bacteriological and clinical cure</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment costs</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>MRSA Infection</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>trimethoprim-sulfamethoxazole (TMP-SMX) plus rifampicin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Linezolid</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>trimethoprim-sulfamethoxazole (TMP-SMX)</intervention_name>
    <description>TMP-SMX (160 mg TMP/ 800 mg SMX IV or PO 3x daily)</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Linezolid</intervention_name>
    <description>Linezolid (600 mg IV or PO twice daily)</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifampicin</intervention_name>
    <description>Rifampicin (600 mg IV or PO once daily)</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age &gt; 18 years&#xD;
&#xD;
          2. Patients with clinical signs and symptoms of MRSA-related infection&#xD;
&#xD;
          3. Culture of MRSA (predominant microorganism in culture) susceptible to all of the&#xD;
             following:&#xD;
&#xD;
               -  TMP-SMX&#xD;
&#xD;
               -  rifampicin&#xD;
&#xD;
               -  linezolid&#xD;
&#xD;
          4. Patient must give written informed consent to participate in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Women who are pregnant or nursing&#xD;
&#xD;
          2. Women who refuse to substitute oral contraception during treatment&#xD;
&#xD;
          3. Known or suspected hypersensitivity to linezolid, TMP-SMX or rifampicin&#xD;
&#xD;
          4. Clinical or laboratory evidence of significant impairment of hepatic function, as&#xD;
             demonstrated by any of the following criteria:&#xD;
&#xD;
               -  Bilirubin &gt; 3 x upper limit of normal range&#xD;
&#xD;
               -  AST or ALT &gt; 5 x upper limit of normal range&#xD;
&#xD;
               -  Acute hepatitis or proven liver cirrhosis by liver histology&#xD;
&#xD;
          5. Treatment with other antimicrobials with activity against MRSA for &gt; 72 hours prior to&#xD;
             study inclusion&#xD;
&#xD;
          6. Patients with a high probability of death within the week following study entry&#xD;
&#xD;
          7. Patients who, in the opinion of the investigator, cannot be relied upon for&#xD;
             post-therapy follow-up&#xD;
&#xD;
          8. Patients requiring alternative antibiotic therapy with anti-MRSA activity. However, if&#xD;
             another antibiotic treatment without antistaphylococcal activity is necessary, the&#xD;
             patient is acceptable for randomization. In that sense, the use of aztreonam (against&#xD;
             Gram negative microorganisms) or metronidazole (against anaerobes) is allowed&#xD;
&#xD;
          9. Hemodialyzed patients&#xD;
&#xD;
         10. History of pheochromocytoma, carcinoid syndrome, untreated hyperthyroidism,&#xD;
             uncontrolled hypertension, or patients receiving serotonin uptake inhibitors&#xD;
&#xD;
         11. Severe thrombocytopenia (&lt; 50.000 platelets)&#xD;
&#xD;
         12. Left-sided endocarditis with a poor prognosis (patients aged over 50; cerebral&#xD;
             embolism)&#xD;
&#xD;
         13. Chronic osteomyelitis without surgical debridement; superinfected indwelling foreign&#xD;
             body, deliberately kept in place&#xD;
&#xD;
         14. Patients with severe sepsis or septic shock due to MRSA bacteremia&#xD;
&#xD;
         15. Patients who receive any of the following drugs, which cannot be substituted or&#xD;
             temporarily withdrawn: adrenergic and serotonergic agents, tramadol, pethidine,&#xD;
             duloxetine, venlafaxine, milnacipran, sibutramine, chlorpheniramine, brompheniramine,&#xD;
             cyproheptadine, citalopram, and paroxetine.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephan Harbarth, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Geneva</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Geneva University Hospitals</name>
      <address>
        <city>Geneva</city>
        <zip>1211</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <link>
    <url>http://medweb1.unige.ch/recherche/groupes/b_donnees/sujet_330_1.html</url>
    <description>MRSA research center, Geneva University Hospitals and Medical School</description>
  </link>
  <verification_date>August 2014</verification_date>
  <study_first_submitted>July 3, 2008</study_first_submitted>
  <study_first_submitted_qc>July 3, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 9, 2008</study_first_posted>
  <last_update_submitted>August 4, 2014</last_update_submitted>
  <last_update_submitted_qc>August 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 5, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Geneva</investigator_affiliation>
    <investigator_full_name>Stephen Harbarth</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Staphylococcal infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rifampin</mesh_term>
    <mesh_term>Linezolid</mesh_term>
    <mesh_term>Trimethoprim, Sulfamethoxazole Drug Combination</mesh_term>
    <mesh_term>Trimethoprim</mesh_term>
    <mesh_term>Sulfamethoxazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

